Stockscreener 앱 받기
1.97
4.37%
-0.09
시간 외 거래:
1.99
0.02
+1.02%
전일 마감가:
$2.06
열려 있는:
$2.04
하루 거래량:
15,855
Relative Volume:
0.32
시가총액:
$77.14M
수익:
$57,000
순이익/손실:
$-32.14M
주가수익비율:
-3.0467
EPS:
-0.6466
순현금흐름:
$-27.58M
1주 성능:
-1.50%
1개월 성능:
-1.50%
6개월 성능:
-46.61%
1년 성능:
-28.62%
1일 변동 폭
$1.9379
$2.0549
1주일 범위
$1.7901
$2.12
52주 변동 폭
$1.56
$3.95
Sera Prognostics Inc Stock (SERA) Company Profile
명칭
Sera Prognostics Inc
전화
(801) 990-0520
주소
2749 E. PARLEYS WAY, SALT LAKE CITY
Compare SERA vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SERA
Sera Prognostics Inc
|
1.97 | 77.14M | 57,000 | -32.14M | -27.58M | -0.6466 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Sera Prognostics Inc Stock (SERA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 개시 | Jefferies | Buy |
| 2022-03-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | Oppenheimer | Outperform |
| 2021-10-15 | 재개 | Cowen | Outperform |
Sera Prognostics Inc 주식(SERA)의 최신 뉴스
Sera Prognostics study shows NICU admission cut in first births - Investing.com
Sera Prognostics study shows NICU admission cut in first births By Investing.com - Investing.com Canada
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE - PR Newswire
Sera Prognostics Among 3 Intriguing Penny Stocks To Consider - simplywall.st
SERASera Prognostics Inc Options - Finviz
Director Mark Christopher Capone files Form 3 for Sera Prognostics (SERA) - Stock Titan
Sera Prognostics, Inc. Class A Actuals & Estimates (NASDAQ:SERA) - TradingView
Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com - Investing.com South Africa
Sera Prognostics, Inc. Appoints Mark Capone as Class II Director and Member of Compensation Committee, Effective as of July 1, 2026 - marketscreener.com
Sera Prognostics adds former Myriad Genetics CEO to board - Investing.com
Sera Prognostics Adds Veteran Executive to Board - TipRanks
Mark Capone appointed to Sera Prognostics board, joins Compensation Committee - TradingView
Veteran diagnostics leader Mark Capone joins Sera Prognostics (NASDAQ: SERA) board - Stock Titan
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS - Aspen Daily News
Sera Prognostics (SERA) Edges Higher as Stock Tests Key Resistance LevelStop Run - dars.gov.et
Sera Prognostics, Inc.(NasdaqGM:SERA) added to Russell Microcap Value Benchmark Index - marketscreener.com
Sera Prognostics, Inc.(NasdaqGM: SERA) added to Russell 3000E Value Benchmark - marketscreener.com
Sera Prognostics, Inc. Class A Actuals & Estimates (BOATS:SERA) - TradingView
SERA Forecast — Price Target — Prediction for 2027 - TradingView
Sera Prognostics (SERA) loses 27% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Price to earnings forward of Sera Prognostics, Inc. – NASDAQ:SERA - TradingView
Enterprise value to revenue forward of Sera Prognostics, Inc. – NASDAQ:SERA - TradingView
Price to sales forward of Sera Prognostics, Inc. – NASDAQ:SERA - TradingView
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH - PR Newswire
Price to book forward of Sera Prognostics, Inc. – NASDAQ:SERA - TradingView
Enterprise value to EBIT forward of Sera Prognostics, Inc. – BOATS:SERA - TradingView
Sera Prognostics joins $10.4M ARPA-H project to develop a rapid test for safer labor and delivery. - Pluang
Illinois expands Medicaid coverage for preterm birth tests By Investing.com - Investing.com South Africa
Illinois expands Medicaid coverage for preterm birth tests - Investing.com UK
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY - PR Newswire
Sera Prognostics Q1 2026 Earnings: In-Line Loss Highlights Pre-Revenue ProgressOperating Margin Analysis - dars.gov.et
All you need to know about Sera Prognostics (SERA) rating upgrade to buy - MSN
All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy - Yahoo Finance
SERA News | SERA PROGNOSTICS INC-A (NASDAQ:SERA) - ChartMill
Sera Prognostics Inc (SERA) Institutional Confidence - TradingKey
Sera Prognostics Inc (SERA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sera Prognostics Inc (SERA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sera Prognostics Inc (SERA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sera Prognostics Inc (SERA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sera Prognostics Inc (SERA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sera Prognostics Inc (SERA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sera Prognostics Inc (SERA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sera Prognostics Inc (SERA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SERA (NASDAQ: SERA) CCO sells 4,739 shares to cover RSU tax withholding - Stock Titan
Sera Prognostics (NASDAQ: SERA) CFO sells shares to cover RSU tax obligations - Stock Titan
SERA PROGNOSTICS (NASDAQ: SERA) CEO tax-related share sale disclosed - Stock Titan
SERA (NASDAQ: SERA) CMO executes 362-share tax sell-to-cover trade - Stock Titan
SERA (SERA) General Counsel sells 2,179 shares to cover RSU taxes - Stock Titan
SERA (NASDAQ) Form 144: Class A Common sales tied to RSU vesting on 06/11/2026 - Stock Titan
Sera Prognostics Q1 2026 Earnings: In-Line EPS as Company Advances Proteomic PlatformEstimate Revision Count - newsline.com
Sera Prognostics CEO Lindgardt sells $43,170 in company stock By Investing.com - Investing.com Canada
Sera Prognostics Inc (SERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.36%
자본화:
|
볼륨(24시간):